Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 30, 2016	Feb. 01, 2016	Apr. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		$ 25.0
Notes receivable	$ 154.0	154.0	$ 0.0
Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration				$ 52.0
Fair value of contingent liability				$ 10.6
Senior Notes | 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage					3.50%
Senior Notes | 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage					4.75%
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	32.6	32.6	$ 33.6
Level 3 | Secured Debt | 4.00% Term Loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			4.00%
Level 3 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash surrender value of life insurance	66.9	66.9	$ 67.6
Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	0.0	0.0	0.0
Level 3 | Recurring | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	103.2	103.2	124.7
Level 3 | Recurring | Stratatech
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	53.3	53.3	55.7
Level 3 | Raplixa | Recurring | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration	60.5	60.5	58.9
Level 3 | PreveLeak | Recurring | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	11.4	11.4	$ 11.2
Level 2 | Debentures | 8.00% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Level 2 | Debentures | 9.50% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			9.50%
Level 2 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	5.0	5.0	$ 11.1
Level 2 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	11.1	11.1	$ 10.8
Level 1 | Senior Notes | 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			3.50%
Level 1 | Senior Notes | 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			4.75%
Level 1 | Senior Notes | 5.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			5.75%
Level 1 | Senior Notes | 4.88% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Level 1 | Senior Notes | 5.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			5.50%
Level 1 | Unsecured Debt | 5.625% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			5.625%
Level 1 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	21.5	21.5	$ 22.8
Maximum | Synacthen | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Milestone Payment	140.0
Indemnification Agreement | Mallinckrodt Baker | Level 1 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Restricted Cash and Cash Equivalents	$ 18.2	$ 18.2	$ 19.1